Design Therapeutics Inc Dossier - Source-backed chat

Design Therapeutics Inc

DSGNNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.44

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $12.24Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $766M

Enterprise Value $753.7M

Shares Outstanding 62.5M diluted

Next Earnings Date31 Dec 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Design Therapeutics is a clinical-stage biotechnology company pioneering a novel class of genomic medicines using its proprietary GeneTAC® platform. Unlike traditional gene therapies or oligonucleotides, GeneTAC® molecules are small-molecule chimeras (1,000-3,000 Daltons) designed to selectively dial up or dial down the expression of disease-causing genes. This approach offers superior tissue distribution and avoids the overexpression risks of larger modalities. The company's investment thesis is highly compelling following positive four-week Phase 1/2 RESTORE-FA data for DT-216P2 in Friedreich's Ataxia (FA), which demonstrated dose-dependent increases in endogenous frataxin (FXN) mRNA and protein alongside significant clinical improvements (6.4-point mFARS improvement at 1 mpk). Backed by a robust cash position of $222.8 million (runway into 2029) and multiple high-impact clinical readouts in 2H 2026, Design Therapeutics represents an asymmetric risk-reward opportunity in the rare genetic disease space.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets6 analysts · as of 18 Aug 2026

Low · most bearish analyst$20.00

Mean target$21.00

High · most bullish analyst$22.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The bear case assumes that longer-term (12-week) dosing of DT-216P2 reveals safety concerns, such as persistent or severe ALT elevations, or fails to show sustained clinical improvements. Additionally, DT-168 fails to show meaningful biomarker activity in FECD, or regulatory hurdles delay clinical progression, forcing the company to restructure its pipeline and accelerating its cash burn.

Base CaseCentral scenario

The base case assumes DT-216P2 continues to show robust safety and sustained frataxin restoration in the 12-week dosing cohorts of the RESTORE-FA trial, supporting a clear registrational path by late 2026. Additionally, the Phase 2 biomarker trial of DT-168 in FECD yields positive safety and biomarker signals in 2H 2026, validating the platform's multi-indication utility. The company's cash runway remains secure into 2029, minimizing near-term dilution risk.

Bull CaseUpside scenario

Design Therapeutics' bull case is driven by its novel GeneTAC platform, which has demonstrated clinical and mechanistic proof-of-concept. In May 2026, the company reported positive four-week Phase 1/2 RESTORE-FA trial data for DT-216P2 in Friedreich ataxia, showing dose-dependent increases in endogenous frataxin (FXN) mRNA and protein alongside significant clinical improvements (such as a 6.4-point mean improvement in mFARS at the 1 mg/kg dose). These strong early efficacy signals support the company's transition toward a registrational development path, with a detailed regulatory update expected in Q4 2026.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Proprietary GeneTAC® platform offers a highly differentiated, small-molecule approach to genomic medicine with superior tissue distribution compared to oligonucleotides and gene therapies.
Strong clinical proof-of-concept established by positive four-week RESTORE-FA data, showing unprecedented concurrent increases in endogenous FXN and clinical improvements (mFARS and Upright Stability).
Excellent financial health with $222.8 million in cash and investments as of Q1 2026, providing an exceptionally long runway into 2029 that covers multiple clinical inflection points.
Diversified clinical pipeline targeting high-value rare disease indications with multi-billion dollar market opportunities (Friedreich's Ataxia, FECD, and Myotonic Dystrophy Type-1).

Key Investment Risks

Clinical development risk inherent to early-stage biotech; longer-term 12-week dosing data for DT-216P2 may not replicate the strong efficacy or safety profile seen in the 4-week data.
Potential safety signals, such as transient ALT elevations observed with mitochondrial activity, could limit dosing or trigger regulatory holds.
Regulatory approval risks, particularly if the FDA requires lengthy clinical endpoint trials rather than biomarker-driven accelerated approval pathways.

Thesis Invalidation Triggers

Failure of DT-216P2 to demonstrate sustained frataxin restoration or acceptable safety in the 12-week RESTORE-FA data update in late 2026.
An unexpected clinical hold by the FDA or other regulatory bodies on any of the lead clinical programs (DT-216P2, DT-168, or DT-818).
A significant increase in quarterly cash burn that materially shortens the projected runway to below late 2028.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.